Home › Compound Library › Salvia (Salvinorin A)

Salvia (Salvinorin A)

Dissociativeoral · inferred

Potent neoclerodane diterpene from Salvia divinorum. First known naturally occurring non-nitrogenous kappa-opioid receptor (KOR) selective full agonist, structurally unrelated to any classical opioid. Extremely rapid onset when smoked/vaporized (30-60 seconds), with intense dissociative/hallucinogenic effects lasting <10 minutes. Brain half-life ~8 minutes; systemic elimination half-life ~56 minutes. No activity at 5-HT2A (unlike classical psychedelics), serotonin, or dopamine receptors.

Projected serum levels — 1 mg, as needed (shown daily)

Salvia (Salvinorin A)
Salvia (Salvinorin A) modeled serum levels, 1 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Salvia (Salvinorin A) modeled serum levels with a loading dose of 1.2 mg, then 1 mg as needed (shown daily) The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 1 mg as needed (shown daily) (oral).

Loading schedule: 1.2 mg on day 1, then 1 mg as needed (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 0.51 mg, trough ≈ 0.12 mg body load. Population-based estimate over 15 days for a 1 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Dissociative
Route modeled
Oral
Model confidence
inferred
Half-life
9.8 h
Common dose
1 mg
Reference dose range
0.50–2 mg (single dose)
Suggested cadence
as needed (shown daily)

Documented interactions

  • moderate
    Berberine + Salvia (Salvinorin A) CYP inhibition

    Berberine reversible_inhibitor of CYP2D6 predicted to change Salvia (Salvinorin A) AUC by ~1.54x

  • moderate
    Bupropion (Wellbutrin) + Salvia (Salvinorin A) CYP inhibition

    Bupropion (Wellbutrin) reversible_inhibitor of CYP2D6 predicted to change Salvia (Salvinorin A) AUC by ~1.54x

  • moderate
    CBD (Cannabidiol) + Salvia (Salvinorin A) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of CYP2D6 predicted to change Salvia (Salvinorin A) AUC by ~1.54x

  • moderate
    Celecoxib (Celebrex) + Salvia (Salvinorin A) CYP inhibition

    Celecoxib (Celebrex) reversible_inhibitor of CYP2D6 predicted to change Salvia (Salvinorin A) AUC by ~1.54x

  • moderate
    Citalopram (Celexa) + Salvia (Salvinorin A) CYP inhibition

    Citalopram (Celexa) reversible_inhibitor of CYP2D6 predicted to change Salvia (Salvinorin A) AUC by ~1.54x

  • moderate
    Contrave (Naltrexone/Bupropion) + Salvia (Salvinorin A) CYP inhibition

    Contrave (Naltrexone/Bupropion) reversible_inhibitor of CYP2D6 predicted to change Salvia (Salvinorin A) AUC by ~1.54x

Serum checks 41 modeled interaction pairings for salvia (salvinorin a) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist Roth BL et al. · Proceedings of the National Academy of Sciences, 2002 DOI

    Landmark discovery paper identifying salvinorin A as the first naturally occurring non-nitrogenous KOR-selective agonist. Demonstrated potent activity at cloned human KOR (Ki = 16 nM) with no significant activity at >50…

  2. Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans Hooker JM et al. · NeuroImage, 2008 DOI

    PET imaging study in non-human primates showing salvinorin A enters brain within seconds, peaks at 40 seconds, and clears with brain half-life of ~8 minutes. Systemic elimination half-life 56.6 +/- 24.8 min.…

  3. Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders Kivell BM et al. · Frontiers in Pharmacology, 2015 DOI

    Review of salvinorin A pharmacology as a selective KOR agonist and its potential as a template for developing novel treatments for addiction, mood disorders, and pain, leveraging its unique non-nitrogenous structure.

3 published studies referenced in the app, each with a plain-language summary.